Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

43.25 +0.05 (+0.12%)
Streaming Delayed Price Updated: 10:42 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
BTIG Research Predicts Over 118% Rally for These 3 Stocks ↗
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. 
Via InvestorPlace
News headline image
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week ↗
A powerfully bullish new analyst take on the company helped it rally on the market. 
Via The Motley Fool
News headline image
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
News headline image
Unveiling 4 Analyst Insights On AnaptysBio ↗
 
Via Benzinga
News headline image
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
Via Benzinga
Topics Stocks
News headline image
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers ↗
AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, foreseeing stock surge amid clinical milestones. Analysis compares PD-1 agonist... 
Via Benzinga
News headline image
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Named a BioSpace 2024 Best Places to Work Winner
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today? ↗
AnaptysBio Inc (NASDAQ: ANAB) released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
News headline image
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session ↗
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
News headline image
AnaptysBio Announces Participation in Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗
 
Via Benzinga
News headline image
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.